I
nvestors wanted Gilead Sciences to shake things up with a big, transformative acquisition and that’s what the company did Monday, agreeing to buy Kite Pharma and its CAR-T cancer-killing technology for $11.9 billion.
Gilead is paying $180 per share, all in cash, for Kite, or a 29 percent premium over its closing stock price Friday.
Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
